Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the U.K. authorized Casgevy for sickle cell disease and beta thalassemia, the world's first regulatory nod for a CRISPR gene editing-based therapeutic. Then, in two separate decisions, the U.S. Food and Drug Administration also approved the gene editing treatment for the blood disorders.

Casgevy is CRISPR Therapeutics' very first product and has blockbuster potential. So, all of this is major news that should lead to revenue growth. CRISPR Therapeutics and partner Vertex Pharmaceuticals are now rolling out the treatment in the U.S. and the U.K. and waiting for additional regulatory decisions in other countries. So, at this key moment in CRISPR Therapeutics' story, could you set yourself off on the path to millions if you invest? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com